retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial 40mg Retatrutide: How the Triple Agonist

[35] reported that a 6-month exenatide-based therapy produced a 42% relative reduction in intrahepatic lipid content, accompanied by a mean BW loss of 5 kg and significant decreases in both abdominal subcutaneous and visceral fat volumes

What that means: For some GLP-1s (particularly semaglutide options like Ozempic), the drug is administered using an injector pen

doi: 10.1016/j.tice.2022.102000, 44

J Neurosci Res (2020) 98(11):235769

La reciente disponibilidad de semaglutida oral puede ayudar a la introduccin precoz de esta familia con beneficios cardiovasculares y renales probados y excelente perfil de seguridad

JAAPA 33:318